185 related articles for article (PubMed ID: 14678339)
1. Population pharmacokinetics of weekly docetaxel in patients with advanced cancer.
Slaviero KA; Clarke SJ; McLachlan AJ; Blair EY; Rivory LP
Br J Clin Pharmacol; 2004 Jan; 57(1):44-53. PubMed ID: 14678339
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test.
Michael M; Cullinane C; Hatzimihalis A; O'Kane C; Milner A; Booth R; Schlicht S; Clarke SJ; Francis P
Cancer Chemother Pharmacol; 2012 Jan; 69(1):125-35. PubMed ID: 21626050
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms.
Tran A; Jullien V; Alexandre J; Rey E; Rabillon F; Girre V; Dieras V; Pons G; Goldwasser F; Tréluyer JM
Clin Pharmacol Ther; 2006 Jun; 79(6):570-80. PubMed ID: 16765145
[TBL] [Abstract][Full Text] [Related]
4. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel.
Engels FK; Ten Tije AJ; Baker SD; Lee CK; Loos WJ; Vulto AG; Verweij J; Sparreboom A
Clin Pharmacol Ther; 2004 May; 75(5):448-54. PubMed ID: 15116057
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics of docetaxel.
Clarke SJ; Rivory LP
Clin Pharmacokinet; 1999 Feb; 36(2):99-114. PubMed ID: 10092957
[TBL] [Abstract][Full Text] [Related]
6. Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.
Engels FK; Mathot RA; Loos WJ; van Schaik RH; Verweij J
Cancer Biol Ther; 2006 Jul; 5(7):833-9. PubMed ID: 16775418
[TBL] [Abstract][Full Text] [Related]
7. Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.
Baker SD; Zhao M; Lee CK; Verweij J; Zabelina Y; Brahmer JR; Wolff AC; Sparreboom A; Carducci MA
Clin Cancer Res; 2004 Mar; 10(6):1976-83. PubMed ID: 15041715
[TBL] [Abstract][Full Text] [Related]
8. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance.
Hirth J; Watkins PB; Strawderman M; Schott A; Bruno R; Baker LH
Clin Cancer Res; 2000 Apr; 6(4):1255-8. PubMed ID: 10778948
[TBL] [Abstract][Full Text] [Related]
9. Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol.
Yamamoto N; Tamura T; Kamiya Y; Sekine I; Kunitoh H; Saijo N
J Clin Oncol; 2000 Jun; 18(11):2301-8. PubMed ID: 10829051
[TBL] [Abstract][Full Text] [Related]
10. Significant effect of age on docetaxel pharmacokinetics in Japanese female breast cancer patients by using the population modeling approach.
Onoue H; Yano I; Tanaka A; Itohara K; Hanai A; Ishiguro H; Motohashi H; Masuda S; Matsubara K
Eur J Clin Pharmacol; 2016 Jun; 72(6):703-10. PubMed ID: 26905999
[TBL] [Abstract][Full Text] [Related]
11. Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol.
Yamamoto N; Tamura T; Murakami H; Shimoyama T; Nokihara H; Ueda Y; Sekine I; Kunitoh H; Ohe Y; Kodama T; Shimizu M; Nishio K; Ishizuka N; Saijo N
J Clin Oncol; 2005 Feb; 23(6):1061-9. PubMed ID: 15657405
[TBL] [Abstract][Full Text] [Related]
12. Predicting the toxicity of weekly docetaxel in advanced cancer.
Charles KA; Rivory LP; Stockler MR; Beale P; Beith J; Boyer M; Clarke SJ
Clin Pharmacokinet; 2006; 45(6):611-22. PubMed ID: 16719542
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.
Blair EY; Rivory LP; Clarke SJ; McLachlan AJ
Br J Clin Pharmacol; 2004 Apr; 57(4):416-26. PubMed ID: 15025739
[TBL] [Abstract][Full Text] [Related]
14. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies.
Goh BC; Lee SC; Wang LZ; Fan L; Guo JY; Lamba J; Schuetz E; Lim R; Lim HL; Ong AB; Lee HS
J Clin Oncol; 2002 Sep; 20(17):3683-90. PubMed ID: 12202670
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and toxicity of weekly docetaxel in older patients.
Hurria A; Fleming MT; Baker SD; Kelly WK; Cutchall K; Panageas K; Caravelli J; Yeung H; Kris MG; Gomez J; Miller VA; D'Andrea G; Scher HI; Norton L; Hudis C
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6100-5. PubMed ID: 17062686
[TBL] [Abstract][Full Text] [Related]
16. Lack of association of single-nucleotide polymorphisms in pregnane X receptor, hepatic nuclear factor 4alpha, and constitutive androstane receptor with docetaxel pharmacokinetics.
Tham LS; Holford NH; Hor SY; Tan T; Wang L; Lim RC; Lee HS; Lee SC; Goh BC
Clin Cancer Res; 2007 Dec; 13(23):7126-32. PubMed ID: 18056193
[TBL] [Abstract][Full Text] [Related]
17. Dexamethasone as a probe for docetaxel clearance.
Puisset F; Chatelut E; Dalenc F; Busi F; Cresteil T; Azéma J; Poublanc M; Hennebelle I; Lafont T; Chevreau C; Roché H
Cancer Chemother Pharmacol; 2004 Sep; 54(3):265-72. PubMed ID: 15133628
[TBL] [Abstract][Full Text] [Related]
18. The influence of granisetron on the pharmacokinetics and pharmacodynamics of docetaxel in Asian lung cancer patients.
Miyata M; Yasuda K; Burioka N; Takane H; Suyama H; Shigeoka Y; Endo M; Kurai J; Morita M; Igishi T; Shimizu E
Cancer J; 2006; 12(1):69-72. PubMed ID: 16613665
[TBL] [Abstract][Full Text] [Related]
19. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients.
Nygren P; Hande K; Petty KJ; Fedgchin M; van Dyck K; Majumdar A; Panebianco D; de Smet M; Ahmed T; Murphy MG; Gottesdiener KM; Cocquyt V; van Belle S
Cancer Chemother Pharmacol; 2005 Jun; 55(6):609-16. PubMed ID: 15723220
[TBL] [Abstract][Full Text] [Related]
20. Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay.
Gustafson DL; Long ME; Zirrolli JA; Duncan MW; Holden SN; Pierson AS; Eckhardt SG
Cancer Chemother Pharmacol; 2003 Aug; 52(2):159-66. PubMed ID: 12759775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
